NCT03409458 - A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

June 1, 2022

Study Completion Date

August 31, 2022

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

PT-112

"The RP2D of PT-112 when used in combination with avelumab has been determined during dose escalation and is being confirmed in the NSCLC dose confirmation cohort.~For the NSCLC confirmation cohort, PT-112 will be administered at a dose of 360 mg/m2 on Days 1, 8 and 15."

BIOLOGICAL

avelumab

Avelumab will be administered at a fixed dose of 800 mg on Days 1 and 15.

Trial Locations (6)

1011

Lausanne, Lausanne

32224

Florida, Jacksonville

55905

Minnesota, Rochester

77030

University of Texas MD Anderson Cancer Center, Houston

80045

Colorado, Aurora

85054

Arizona, Phoenix